Overview

A Trial to Compare the Efficacy, Safety, Pharmacokinetics and Immunogenecity of HD204 to Avastin® in Advanced Non-squamous Non-small Cell Lung Cancer Patients

Status:
Recruiting

Trial end date:
2022-12-01

Target enrollment:

Participant gender:

Summary

In the SAMSON-2 study, the proposed biosimilar HD204 will be compared to its reference product EU-licensed Avastin®. The aim of the study is to demonstrate equivalence of HD204 and EU-licensed Avastin® in terms of efficacy, safety, pharmacokinetics and immunogenecity.

Phase:

Phase 3

Details

Lead Sponsor:

Prestige Biopharma Limited
Prestige Biopharma Ltd

Treatments:

Bevacizumab
Carboplatin
Paclitaxel